Limited Submission Opportunities – Open Calls
Institutionally Coordinated Submissions
Welcome to the current listing of open limited submission opportunities available through the ORSD. These opportunities represent competitive funding programs in which the sponsor limits the number of applications an institution may submit. To ensure a fair and strategic selection process, ORSD coordinates internal reviews and nominations when necessary.
Each listing includes key details such as eligibility criteria, internal deadlines, sponsor deadlines, and links to full program guidelines. Faculty and researchers are encouraged to review these opportunities regularly and begin preparing proposals early.
If you are aware of a limited submission opportunity that is not listed, please email the RDTE%20Information%20Specialist to ensure it is reviewed and appropriately coordinated.
Open Calls
RDEA Pilot Program Internal Competition Now Open
First Quarter Submission
Running from Monday, January 12 - Friday, January 16, 5:00 PM (CST)
IC Notification: Week of January 26, 2026
(Limited to 1 nomination per institution)
U. S. Department of Agriculture Food & Drug Administration
FDA-2022-N-2480
The RDEA Pilot Program is a joint program of the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. The program is designed to:
- Seek to advance rare disease drug development programs by providing a mechanism for sponsors to collaborate with FDA throughout the efficacy endpoint development process.
- Promote innovation and evolving science by sharing learnings on novel endpoint development through FDA presentations, guidance documents, public workshops, and a public-facing website.
- Develop FDA staff capacity to enable and facilitate the development and use of novel endpoints to evaluate the efficacy of rare disease therapies.
FDA welcomes RDEA proposals related to any eligible novel endpoint for a rare disease. For fiscal years 2024 through 2027, FDA will accept up to one RDEA proposal per quarter with a maximum of three RDEA proposals per year.
The institution will conduct one internal competition per FDA quarterly RDEA submission deadline. The competition referenced on this page pertains only to the First Quarter (March 31) submission. Additional competitions will be announced in advance of the June 30, September 30, and December 31 deadlines.
Upcoming Opportunities
PAR-23-077 Collaborative Program Grant for Multidisciplinary Teams
(RM1 - Clinical Trial Optional)
Sponsor: U.S. Department of Health and Human Services – National Institutes of Health – National Institute for General Medical Sciences
The Collaborative Program Grant is designed to support research in which funding a team of interdependent investigators to achieve a unified scientific goal offers significant advantages over supporting individual research project grants.
IC: February 9, 2026 - February 13, 2026
Notifications: Week of February 23, 2026
Sponsor Deadline: May 27, 2026